Nanobiotix (NASDAQ:NBTX) Sees Strong Trading Volume – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw unusually-high trading volume on Monday . Approximately 60,917 shares were traded during trading, a decline of 3% from the previous session’s volume of 62,664 shares.The stock last traded at $39.4320 and had previously closed at $38.40.

Analysts Set New Price Targets

NBTX has been the subject of several recent research reports. TD Cowen restated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. UBS Group lifted their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Guggenheim boosted their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.33.

Nanobiotix Stock Up 6.4%

The firm has a 50 day simple moving average of $39.09 and a 200-day simple moving average of $31.06.

Institutional Trading of Nanobiotix

Institutional investors have recently modified their holdings of the company. Royal Bank of Canada grew its position in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the last quarter. Marshall Wace LLP purchased a new stake in Nanobiotix during the fourth quarter valued at approximately $220,000. Finally, Millennium Management LLC purchased a new stake in Nanobiotix during the fourth quarter valued at approximately $390,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.